The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Jevtana
(United States) [Available]Synonyms :
cabazitaxel
Class :
Antineoplastics, Antimicrotubular
Brand Name :
Jevtana
(United States) [Available]Synonyms :
cabazitaxel
Class :
Antineoplastics, Antimicrotubular
Dosage forms & Strengths:
KitÂ
Each kit contains: 60mg/1.5mL cabazitaxel injection along with 5.7mL diluentÂ
Metastatic cancer:
20
mg/m^2
Intravenous (IV)
every 3 weeks
in combination with prednisone 10 mg orally throughout the treatment.
Dose Adjustments
Grade ≥3 diarrhea despite appropriate medication, fluid, and electrolyte replacement: Delay treatment until improvement or resolution, then reduce dose by 1 level.
Grade 2 peripheral neuropathy, delay treatment and reduce dose by 1 level.
Grade >3 peripheral neuropathy Discontinue.
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
may enhance the serum concentration of CYP3A4 inhibitors
may increase excessive immunosuppressive effects and risk of infection
adenovirus types and live oral
may reduce therapeutic effects of the vaccine
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
may raise the risk of neutropenia due to myelosuppression
increase immunosuppressive effects and risk of infection
may raise the risk of pancytopenia and agranulocytosis due to myelosuppression
may increase bone marrow suppression
increases the serum concentration of BCRP/ABCG2 substrates
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
increased toxic adverse effects of cabazitaxel
may increase bone marrow suppression
increase immunosuppressive effects and risk of infection
when both drugs are combined, there may be an increased effect of cabazitaxel by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of cabazitaxel
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increase immunosuppressive effects and risk of infection
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases the serum concentration of cabazitaxel by MDR1 efflux transporter
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may diminish immune response to cholera vaccine c
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may diminish immune response to dengue vaccine
increased risk of serious infection due to impaired immune system
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases the serum concentration of cabazitaxel by MDR1 efflux transporter
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance and prolong the myelosuppression activity
may enhance immunosuppression and myelosuppression
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may increase excessive immunosuppressive effects
may diminish therapeutic effects of sipuleucel-T
may enhance the risk of neutropenia due to immunosuppression
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
it may diminish the metabolism when combined with zuclopenthixol
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
When cabazitaxel is used together with fluconazole, this leads to reduction in the cabazitaxel metabolism
When cabazitaxel is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
When cabazitaxel is used together with oleandomycin, this leads to enhanced concentration serum of cabazitaxel
When cabazitaxel is used together with patupilone, this leads to enhanced concentration serum of cabazita
When cabazitaxel is used together with ridaforolimus, this leads to enhanced concentration serum of cabazitaxel
when both drugs are combined, there may be a high metabolism of cabazitaxel  
may increase the risk or severity of toxic effects when combined
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
Action and SpectrumÂ
It intervenes with the normal process of cell division, leading to the death of cancer cells. Microtubule stability is an important component of cell division. By stabilizing microtubules and it slows down the rate of cell division and prevents the growth of cancer cells.Â
Frequency DefinedÂ
10%Â
Anemia Â
Leukopenia Â
Fatigue Â
Nausea Â
Diarrhea Â
NeutropeniaÂ
1-10%Â
Dyspepsia Â
Alopecia Â
Weight loss Â
Dizziness Â
Peripheral edema Â
Dysuria Â
Blackbox warningÂ
Serious hypersensitivity response may be fatal Â
Contraindications/CautionÂ
HypersensitivityÂ
NeutropeniaÂ
Liver impairmentÂ
Pregnancy consideration: cabazitaxel is assigned under pregnancy category C. It should be used with caution for pregnant women.Â
Lactation: No data available for excretion in breast milk, it should be avoided due to potential side effectsÂ
Pregnancy category:Â
Â
PharmacologyÂ
By binding to the beta-tubulin subunit’s N-terminal amino acids the drug inhibits disassembly and promotes microtubule polymerization. Therefore it stabilizes microtubules and stops the cell division.Â
PharmacodynamicsÂ
It does have a direct cytotoxic effect on cancer cells which is leading to cell death. Â
PharmacokineticsÂ
AbsorptionÂ
Peak plasma-1 hourÂ
Area under the curve-991 ngâ‹…h/mLÂ
DistributionÂ
Volume of distribution- 4864 LÂ Â
MetabolismÂ
It is metabolised in the liver and the primary metabolites are hydroxy cabazitaxel and hydroxy docetaxelÂ
EliminationÂ
Terminal half-life- 95 hoursÂ
76% of the drug is excreted in feces and 3.7% in urineÂ
AdministrationÂ
Intravenous route is preferredÂ
Patient information leafletÂ
Generic Name: cabazitaxelÂ
Pronounced: ka-BAZ-i-TAX-elÂ
Why do we use cabazitaxel?Â
Cabacitaxel is used in combination with corticosteroids to treat metastatic castration-resistant prostate cancer in individuals who have already had treatment with a regimen that includes docetaxel.Â
When combined with prednisone, cabacitaxel is recommended for the treatment of patients with metastatic castration-resistant prostate cancer.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
